Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Sunitinib
Sponsor: SCRI Development Innovations, LLC
Collaborators: Pfizer